5′-Phosphate oligodeoxynucleotides enhance the phosphodiester-CpG DNA-induced inflammatory response in macrophages

European Journal of Immunology

Volumn 41, Issue 2, 2011, Pages 425-436

  Yoshida, Hiroyuki ^a   Nishikawa, Makiya ^a   Kiyota, Tsuyoshi ^a   Uno, Shota ^a   Toyota, Hiroyasu ^a   Takahashi, Rei ^b   Narita, Miwako ^c   Takakura, Yoshinobu ^a  

^a KYOTO UNIVERSITY   (Japan)

^b DOSHISHA WOMEN'S COLLEGE OF LIBERAL ARTS   (Japan)

^c NIIGATA UNIVERSITY   (Japan)

Author keywords

5 Phosphate; CpG motif; Cytokines; DNase I; Macrophages

Indexed keywords

5' PHOSPHATE OLIGODEOXYNUCLEOTIDE; DEOXYRIBONUCLEASE I; DEOXYRIBONUCLEASE II; DEOXYRIBONUCLEOTIDE; NUCLEOTIDE; OLIGODEOXYNUCLEOTIDE DERIVATIVE; PHOSPHODIESTERASE; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 7; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; AMINOQUINOLINE DERIVATIVE; CPG OLIGONUCLEOTIDE; CPG-OLIGONUCLEOTIDE; DEOXYRIBONUCLEASE; IMIQUIMOD; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; OLIGODEOXYRIBONUCLEOTIDE; ORGANOPHOSPHATE; POLYINOSINIC POLYCYTIDYLIC ACID; TLR9 PROTEIN, MOUSE; TOLL LIKE RECEPTOR 9;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; AUTOIMMUNE DISEASE; CONTROLLED STUDY; CPG ISLAND; CYTOKINE PRODUCTION; DISEASE EXACERBATION; FOOT PAD; IMMUNE RESPONSE; INFLAMMATION; MACROPHAGE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SWELLING; ANIMAL; C57BL MOUSE; CHEMICALLY INDUCED DISORDER; CYTOLOGY; DENDRITIC CELL; DRUG EFFECT; DRUG POTENTIATION; ENDOCYTOSIS; FOOT; GENETICS; METABOLISM; MOUSE MUTANT; PATHOLOGY; PHYSIOLOGY; PLASMID; SPLEEN; TUMOR CELL LINE;

AMINOQUINOLINES; ANIMALS; CELL LINE, TUMOR; DENDRITIC CELLS; DEOXYRIBONUCLEASE I; DRUG SYNERGISM; ENDOCYTOSIS; ENDODEOXYRIBONUCLEASES; FOOT; INFLAMMATION; INTERLEUKIN-6; LIPOPOLYSACCHARIDES; MACROPHAGES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NUCLEOTIDES; OLIGODEOXYRIBONUCLEOTIDES; PHOSPHORIC ACID ESTERS; PLASMIDS; POLY I-C; SPLEEN; TOLL-LIKE RECEPTOR 9; TUMOR NECROSIS FACTOR-ALPHA;

EID: 78851469466     PISSN: 00142980     EISSN: 15214141     Source Type: Journal    
DOI: 10.1002/eji.201040396     Document Type: Article

References (47)

1. Krieg, A. M., Yi, A. K., Matson, S., Waldschmidt, T. J., Bishop, G. A., Teasdale, R., Koretzky, G. A. and Klinman, D. M., CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 1995. 374: 546-549.
2. Hemmi, H., Takeuchi, O., Kawai, T., Kaisho, T., Sato, S., Sanjo, H., Matsumoto, M. et al., A Toll-like receptor recognizes bacterial DNA. Nature 2000. 408: 740-745.
3. Ahmad-Nejad, P., Hacker, H., Rutz, M., Bauer, S., Vabulas, R. M. and Wagner, H., Bacterial CpG-DNA and lipopolysaccharides activate Toll-like receptors at distinct cellular compartments. Eur. J. Immunol. 2002. 32: 1958-1968.
4. Takeshita, F., Leifer, C. A., Gursel, I., Ishii, K. J., Takeshita, S., Gursel, M. and Klinman, D. M., Cutting edge: Role of Toll-like receptor 9 in CpG DNA-induced activation of human cells. J. Immunol. 2001. 167: 3555-3558.
5. Barton, G. M., Kagan, J. C. and Medzhitov, R., Intracellular localization of Toll-like receptor 9 prevents recognition of self DNA but facilitates access to viral DNA. Nat. Immunol. 2006. 7: 49-56.
6. Means, T. K. and Luster, A. D., Toll-like receptor activation in the pathogenesis of systemic lupus erythematosus. Ann. N. Y. Acad. Sci. 2005. 1062: 242-251.
7. Amoura, Z., Piette, J. C., Chabre, H., Cacoub, P., Papo, T., Wechsler, B., Bach, J. F. and Koutouzov, S., Circulating plasma levels of nucleosomes in patients with systemic lupus erythematosus: correlation with serum antinucleosome antibody titers and absence of clear association with disease activity. Arthritis Rheum. 1997. 40: 2217-2225.
8. Bruneau, C. and Benveniste, J., Circulating DNA:anti-DNA complexes in systemic lupus erythematosus. Detection and characterization by ultracentrifugation. J. Clin. Invest. 1979. 64: 191-198.
9. Licht, R., van Bruggen, M. C., Oppers-Walgreen, B., Rijke, T. P. and Berden, J. H., Plasma levels of nucleosomes and nucleosome-autoantibody complexes in murine lupus: effects of disease progression and lipopolyssacharide administration. Arthritis Rheum. 2001. 44: 1320-1330.
10. Burdick, G. and Emlen, W., Effect of antibody excess on the size, stoichiometry, and DNAse resistance of DNA anti-DNA immune complexes. J. Immunol. 1985. 135: 2593-2597.
11. Emlen, W., Ansari, R. and Burdick, G., DNA-anti-DNA immune complexes. Antibody protection of a discrete DNA fragment from DNase digestion in vitro. J. Clin. Invest. 1984. 74: 185-190.
12. Sano, H., Takai, O., Harata, N., Yoshinaga, K., Kodama-Kamada, I. and Sasaki, T., Binding properties of human anti-DNA antibodies to cloned human DNA fragments. Scand. J. Immunol. 1989. 30: 51-63.
13. Matsuda, M. and Ogoshi, H., Specificity of DNase I. Estimation of nucleosides present at the 5'-phosphate terminus of a limit digest of DNA by DNase I. J. Biochem. 1966. 59: 230-235.
14. Compton, L. J., Steinberg, A. D. and Sano, H., Nuclear DNA degradation in lymphocytes of patients with systemic lupus erythematosus. J. Immunol. 1984. 133: 213-216.
15. Sano, H., Imokawa, M., Steinberg, A. D. and Morimoto, C., Accumulation of guanine-cytosine-enriched low M.W. DNA fragments in lymphocytes of patients with systemic lupus erythematosus. J. Immunol. 1983. 130: 187-190.
16. Yoshida, H., Nishikawa, M., Yasuda, S., Mizuno, Y. and Takakura, Y., Cellular activation by plasmid DNA in various macrophages in primary culture. J. Pharm. Sci. 2008. 97: 4575-4585.
17. Narita, M., Watanabe, N., Yamahira, A., Hashimoto, S., Tochiki, N., Saitoh, A., Kaji, M. et al., A leukemic plasmacytoid dendritic cell line, PMDC05, with the ability to secrete IFN-alpha by stimulation via Toll-like receptors and present antigens to naive T cells. Leuk. Res. 2009. 33: 1224-1232.
18. Takaoka, A., Wang, Z., Choi, M. K., Yanai, H., Negishi, H., Ban, T., Lu, Y. et al., DAI (DLM-1/ZBP1) is a cytosolic DNA sensor and an activator of innate immune response. Nature 2007. 448: 501-505.
19. Ishii, K. J., Kawagoe, T., Koyama, S., Matsui, K., Kumar, H., Kawai, T., Uematsu, S. et al., TANK-binding kinase-1 delineates innate and adaptive immune responses to DNA vaccines. Nature 2008. 451: 725-729.
20. Hemmi, H., Kaisho, T., Takeuchi, O., Sato, S., Sanjo, H., Hoshino, K., Horiuchi, T. et al., Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat. Immunol. 2002. 3: 196-200.
21. Lee, J., Chuang, T. H., Redecke, V., She, L., Pitha, P. M., Carson, D. A., Raz, E. and Cottam, H. B., Molecular basis for the immunostimulatory activity of guanine nucleoside analogs: activation of Toll-like receptor 7. Proc. Natl. Acad. Sci. USA 2003. 100: 6646-6651.
22. Takeshita, F., Gursel, I., Ishii, K. J., Suzuki, K., Gursel, M. and Klinman, D. M., Signal transduction pathways mediated by the interaction of CpG DNA with Toll-like receptor 9. Semin. Immunol. 2004. 16: 17-22.
23. Anders, H. J., A Toll for lupus. Lupus 2005. 14: 417-422.
24. Krieg, A. M., CpG DNA: a pathogenic factor in systemic lupus erythematosus? J. Clin. Immunol. 1995. 15: 284-292.
25. O'Connor, P. J., Salisbury, J. G. and Margison, G. P., Resistance of alkylated DNA to degradation by deoxyribonuclease II at neutral and acid pH. Chem. Biol. Interact. 1976. 14: 313-323.
26. Yasuda, K., Rutz, M., Schlatter, B., Metzger, J., Luppa, P. B., Schmitz, F., Haas, T. et al., CpG motif-independent activation of TLR9 upon endosomal translocation of "natural" phosphodiester DNA. Eur. J. Immunol. 2006. 36: 431-436.
27. Haas, T., Metzger, J., Schmitz, F., Heit, A., Muller, T., Latz, E. and Wagner, H., The DNA sugar backbone 2' deoxyribose determines toll-like receptor 9 activation. Immunity 2008. 28: 315-323.
28. Raptis, L. and Menard, H. A., Quantitation and characterization of plasma DNA in normals and patients with systemic lupus erythematosus. J. Clin. Invest. 1980. 66: 1391-1399.
29. Zwiorek, K., Bourquin, C., Battiany, J., Winter, G., Endres, S., Hartmann, G. and Coester, C., Delivery by cationic gelatin nanoparticles strongly increases the immunostimulatory effects of CpG oligonucleotides. Pharm. Res. 2008. 25: 551-562.
30. Latz, E., Verma, A., Visintin, A., Gong, M., Sirois, C. M., Klein, D. C., Monks, B. G. et al., Ligand-induced conformational changes allosterically activate Toll-like receptor 9. Nat. Immunol. 2007. 8: 772-779.
31. Heeg, K., Dalpke, A., Peter, M. and Zimmermann, S., Structural requirements for uptake and recognition of CpG oligonucleotides. Int. J. Med. Microbiol. 2008. 298: 33-38.
32. Wu, C. C., Lee, J., Raz, E., Corr, M. and Carson, D. A., Necessity of oligonucleotide aggregation for toll-like receptor 9 activation. J. Biol. Chem. 2004. 279: 33071-33078.
33. Napirei, M., Karsunky, H., Zevnik, B., Stephan, H., Mannherz, H. G. and Moroy, T., Features of systemic lupus erythematosus in Dnase1-deficient mice. Nat. Genet. 2000. 25: 177-181.
34. Yasutomo, K., Horiuchi, T., Kagami, S., Tsukamoto, H., Hashimura, C., Urushihara, M. and Kuroda, Y., Mutation of DNASE1 in people with systemic lupus erythematosus. Nat. Genet. 2001. 28: 313-314.
35. Martinez Valle, F., Balada, E., Ordi-Ros, J. and Vilardell-Tarres, M., DNase 1 and systemic lupus erythematosus. Autoimmun. Rev. 2008. 7: 359-363.
36. Davis, J. C., Jr., Manzi, S., Yarboro, C., Rairie, J., McInnes, I., Averthelyi, D., Sinicropi, D. et al., Recombinant human Dnase I (rhDNase) in patients with lupus nephritis. Lupus 1999. 8: 68-76.
37. Martinez-Valle, F., Balada, E., Ordi-Ros, J., Bujan-Rivas, S., Sellas-Fernandez, A. and Vilardell-Tarres, M., DNase 1 activity in patients with systemic lupus erythematosus: relationship with epidemiological, clinical, immunological and therapeutical features. Lupus 2009. 18: 418-423.
38. Chen, Y., Lenert, P., Weeratna, R., McCluskie, M., Wu, T., Davis, H. L. and Krieg, A. M., Identification of methylated CpG motifs as inhibitors of the immune stimulatory CpG motifs. Gene Ther. 2001. 8: 1024-1032.
39. Gursel, I., Gursel, M., Yamada, H., Ishii, K. J., Takeshita, F. and Klinman, D. M., Repetitive elements in mammalian telomeres suppress bacterial DNA-induced immune activation. J. Immunol. 2003. 171: 1393-1400.
40. Lenert, P. S., Classification, mechanisms of action, and therapeutic applications of inhibitory oligonucleotides for Toll-like receptors (TLR) 7 and 9. Mediators Inflamm. 2010. 2010: 986596.
41. Barrat, F. J., Meeker, T., Chan, J. H., Guiducci, C. and Coffman, R. L., Treatment of lupus-prone mice with a dual inhibitor of TLR7 and TLR9 leads to reduction of autoantibody production and amelioration of disease symptoms. Eur. J. Immunol. 2007. 37: 3582-3586.
42. Lenert, P., Yasuda, K., Busconi, L., Nelson, P., Fleenor, C., Ratnabalasuriar, R. S., Nagy, P. L. et al., DNA-like class R inhibitory oligonucleotides (INH-ODNs) preferentially block autoantigen-induced B-cell and dendritic cell activation in vitro and autoantibody production in lupus-prone MRL-Fas(lpr/lpr) mice in vivo. Arthritis Res. Ther. 2009. 11: R79.
43. Patole, P. S., Zecher, D., Pawar, R. D., Grone, H. J., Schlondorff, D. and Anders, H. J., G-rich DNA suppresses systemic lupus. J. Am. Soc. Nephrol. 2005. 16: 3273-3280.
44. Nomura, T., Yasuda, K., Yamada, T., Okamoto, S., Mahato, R. I., Watanabe, Y., Takakura, Y. and Hashida, M., Gene expression and antitumor effects following direct interferon (IFN)-gamma gene transfer with naked plasmid DNA and DC-chol liposome complexes in mice. Gene Ther. 1999. 6: 121-129.
45. Klinman, D. M., Yi, A. K., Beaucage, S. L., Conover, J. and Krieg, A. M., CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. Proc. Natl. Acad. Sci. USA 1996. 93: 2879-2883.
46. Mitsui, M., Nishikawa, M., Zang, L., Ando, M., Hattori, K., Takahashi, Y., Watanabe, Y. and Takakura, Y., Effect of the content of unmethylated CpG dinucleotides in plasmid DNA on the sustainability of transgene expression. J. Gene Med. 2009. 11: 435-443.
47. Yasuda, K., Kawano, H., Yamane, I., Ogawa, Y., Yoshinaga, T., Nishikawa, M. and Takakura, Y., Restricted cytokine production from mouse peritoneal macrophages in culture in spite of extensive uptake of plasmid DNA. Immunology 2004. 111: 282-290.